News & Updates

The novel neurokinin-1 and -3 receptor antagonist elinzanetant appears to reduce the frequency and severity of vasomotor symptoms (VMS), as well as improve sleep and menopause-related quality of life, as shown in two pivotal phase III trials.

Both symptomatic and asymptomatic hypotension are associated with worse outcomes during treatment with either enalapril or sacubitril/valsartan, but the benefits derived from the combination therapy are maintained or even improved in heart failure (HF) patients with hypotension, a study has shown.

Patients with obstructive hypertrophic cardiomyopathy (oHCM) can derive broad clinical benefits from treatment with aficamten, which include complete haemodynamic response and improved exercise capacity among others, as shown by the results of the SEQUOIA-HCM study.